HAL Allergy Group Company Profile: Funding & Investors

HAL Allergy Group Overview

Founded
1959

Status
Private

Employees
300

Latest Deal Type
Buyout/LBO

Financing Rounds
2

HAL Allergy Group General Information

Description

Developer and manufacturer of therapeutic and diagnostic agents focused on allergen immunotherapy. The company develops and produces vaccines, allergy detection and treatment products used for therapeutic and diagnostic purposes, against common allergies such as hay fever, house dust mites allergy and allergic reactions towards wasp or bee stings.

Contact Information

Website

www.hal-allergy.com

Ownership Status

Privately Held (backing)

Financing Status

Private Equity-Backed

Primary Industry

Pharmaceuticals

Other Industries

Biotechnology

Primary Office

J.H. Oortweg 15-17
2333 CH Leiden
Netherlands

+31 088 000 0000







Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

HAL Allergy Group Valuation & Funding

Deal Type	Date	Amount	Valuation/ EBITDA	Post-Val	Status	Debt

This information is available in the PitchBook Platform. To explore HAL Allergy Group‘s full profile, request access.

Request a free trial

HAL Allergy Group Executive Team (7)

Name	Title	Board Seat	Contact Info
Harry Flore	Chief Executive Officer
Florian Rösch	Chief Commercial & Financial Officer & Board Member
Eize de Boer Ph.D	Chief Operating Officer & Board Member
Hans van Schijndel Ph.D	Chief Research & Development Officer
Johan Kuijper	Founder

You’re viewing 5 of 7 executive team members. Get the full list »

HAL Allergy Group Board Members (3)

Name	Representing	Role	Since
0000 00 0000 00.0	HAL Allergy Group	Chief Operating Officer & Board Member	000 0000
0000000 0ö000	HAL Allergy Group	Chief Commercial & Financial Officer & Board Member	000 0000